# US 2001/0036955 A1 · Method of inhibiting angiogenesis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0036955 A1
- Document ID: US20010036955A1
- Status: Published application
- Kind: A1
- Application number: 09/865,859
- Filed: 2001-05-25
- Published: 2001-11-01
- Earliest claimed: 1998-11-20
- Assignees: Genentech, Inc.
- Inventors: Mary E. Gerritsen; Xiaohua E. Xin
- Web page: https://patentgrep.com/patent/US20010036955A1

## CPC

- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/426: 1,3-Thiazoles
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Q 1/37: involving peptidase or proteinase
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 2333/515: Angiogenesic factors; Angiogenin
- G01N 2333/96486: Metalloendopeptidases (3.4.24)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Angiogenesis is inhibited and the growth of tumors is treated by administering an effective amount of a PPAR gamma ligand/agonist, optionally with an RXR receptor ligand.

## Claims

### Claim 1

A method of inhibiting angiogenesis comprising:
(a) identifying a patient in need of an angiogenesis inhibitor; and
(b) administering to the patient a therapeutically effective amount of a PPAR gamma ligand, wherein angiogenesis is inhibited in the patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient is a mammal.

### Claim 3 (depends on 2)

The method of claim 2, wherein the mammal is human.

### Claim 4 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of a PPAR gamma ligand is an angiogenesis inhibiting amount.

### Claim 5 (depends on 1)

The method of claim 1, further comprising administering a therapeutically effective amount of an RXR receptor ligand.

### Claim 6 (depends on 1)

The method of claim 1, wherein the PPAR gamma ligand is selected from the group consisting of (+)-5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione: (troglitazone); 5-[4-[2-(5-ethylpyridin-2-yl)ethoxyl]benzyl]thiadiazolidine-2,4-dione: (pioglitazone); 5-[4-[(1-methylcyclohexyl)methoxy]benzyl]thiadiazolidine-2,4-dione: (ciglitazone); 4-(2-naphthylmethyl)-1,2,3,5-oxathiadiazole-2-oxide; 5-[4-[2-[N-(benzoxazol-2-yl)-N-methylamino]ethoxy]benzyl]-5-methylthiazolidine-2,4-dione; 5-[4-[2-[2,4-dioxo-5-phenylthiazolidin-3-yl) ethoxy]benzyl]thiazolidine-2,4-dione; 5-[4-[2[N-methyl-N-(phenoxycarbonyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione; 5-[4-[2-phenoxyethoxy)benzyl]thiazolidine-2,4-dione; 5-[4-[2-(4-chlorophenyl) ethylsulfonyl]benzyl]thiazolidine-2,4-dione; 5-[4-[3-(5-methyl-2-phenyloxazol-4-yl)propionyl]benzyl]thiazolidine-2,4-dione; 5-[[4-(3-hydroxy-1-methylcyclohexyl)methoxy]benzyl]thiadiazolidine-2,4-dione; 5-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxyl]benzyl]thiadiazolidione-2,4-dione; 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-ylmethyl]thiadiazoline-2,4-dione: (englitazone); 5-[[2-(2-naphthylmethyl)benzoxazol]-5-ylmethyl]thiadiazoline-2,4-dione; 5-[4-[2-(3-phenylureido)ethoxyl]benzyl]thiadiazoline-2,4-dione; 5-[4-[2-[N-(benzoxazol-2-yl)-N-methylamino]ethoxy]benzy]thiadiazoline-2,4-dione; 5-[4-[3-(5-methyl-2-phenyloxazol-4-yl)propionyl]benzyl]thiadiazoline-2,4-dione; 5-[2-(5-methyl-2-phenyloxazol-4-ylmethyl)benzofuran-5-ylmethyl]-oxazolidine-, 4-dione; 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione (BRL 49653); and 5-[4-[2-[N-(benzoxazol-2-yl)-N-methylamino]ethoxy]benzyl]-oxazolidine-2,4-dione.

### Claim 7 (depends on 1)

The method of claim 1, wherein the PPAR gamma ligand is selected from the group consisting of PGA1, PGA2, PGB1, PGB2, PGD1, PGD2, PDJ2, 15-deoxy-12,14-delta-PGJ2, and 12-delta-PGJ2.

### Claim 8 (depends on 1)

The method of claim 1, wherein the PPAR gamma ligand is a fatty acid containing about 10 to about 26 carbon atoms and zero to about 6 carbon-carbon double bonds or carbon-carbon triple bonds.

### Claim 9 (depends on 1)

The method of claim 1, wherein the patient has a disease or disorder characterized by undesirable excessive neovascularization.

### Claim 10 (depends on 9)

The method of claim 9, wherein the disease or disorder is selected from the group consisting of a neoplasm, rheumatoid arthritis, psoriasis, atherosclerosis, diabetic and other retinopathy, endometriosis, retrolental fibroplasia, age-related macular degeneration, neovascular glaucoma, thyroid hyperplasia, tissue transplantation, lung inflammation, obesity, and chronic inflammation.

### Claim 11 (depends on 10)

The method of claim 10, wherein the neoplasm is a solid malignant tumor.

### Claim 12

A method of inhibiting angiogenesis in a patient, comprising:
(a) identifying a patient with a disease or disorder selected from the group consisting of a neoplasm, rheumatoid arthritis, psoriasis, atherosclerosis, thyroid hyperplasia, endometriosis, lung inflammation, obesity, and chronic inflammation; and
(b) administering an angiogenesis inhibiting amount of a PPAR gamma ligand, wherein angiogenesis is inhibited in the patient.

### Claim 13 (depends on 12)

The method of claim 12, wherein the patient is a mammal.

### Claim 14 (depends on 13)

The method of claim 13, wherein the mammal is a human.

### Claim 15 (depends on 12)

The method of claim 12, further comprising administering a therapeutically effective amount of an RXR receptor ligand.

### Claim 16 (depends on 12)

The method of claim 12, wherein the PPAR gamma ligand is selected from the group consisting of (+)-5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione: (troglitazone); 5-[4-[2-(5-ethylpyridin-2-yl)ethoxyl]benzyl]thiadiazolidine-2,4-dione: (pioglitazone); 5-[4-[(1-methylcyclohexyl)methoxy]benzyl]thiadiazolidine-2,4-dione: (ciglitazone); 4-(2-naphthylmethyl)-1,2,3,5-oxathiadiazole-2-oxide; 5-[4-[2-[N-(benzoxazol-2-yl)-N-methylamino]ethoxy]benzyl]-5-methylthiazolidine-2,4-dione; 5-[4-[2-[2,4-dioxo-5-phenylthiazolidin-3-yl) ethoxy]benzyl]thiazolidine-2,4-dione; 5-[4-[2[N-methyl-N-(phenoxycarbonyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione; 5-[4-[2-phenoxyethoxy)benzyl]thiazolidine-2,4-dione; 5-[4-[2-(4-chlorophenyl) ethylsulfonyl]benzyl]thiazolidine-2,4-dione; 5-[4-[3-(5-methyl-2-phenyloxazol-4-yl)propionyl]benzyl]thiazolidine-2,4-dione; 5-[[4-(3-hydroxy-1-methylcyclohexyl)methoxy]benzyl]thiadiazolidine-2,4-dione; 5-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxyl]benzyl]thiadiazolidione-2,4-dione; 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-ylmethyl]thiadiazoline-2,4-dione: (englitazone); 5-[[2-(2-naphthylmethyl)benzoxazol]-5-ylmethyl]thiadiazoline-2,4-dione; 5-[4-[2-(3-phenylureido)ethoxyl]benzyl]thiadiazoline-2,4-dione; 5-[4-[2-[N-(benzoxazol-2-yl)-N-methylamino]ethoxy]benzy]thiadiazoline-2,4-dione; 5-[4-[3-(5-methyl-2-phenyloxazol-4-yl)propionyl]benzyl]thiadiazoline-2,4-dione; 5-[2-(5-methyl-2-phenyloxazol-4-ylmethyl)benzofuran-5-ylmethyl]-oxazolidine-, 4-dione; 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione (BRL 49653); and 5-[4-[2-[N-(benzoxazol-2-yl)-N-methylamino]ethoxy]benzyl]-oxazolidine-2,4-dione.

### Claim 17 (depends on 12)

The method of claim 12, wherein the PPAR gamma ligand is selected from the group consisting of PGA1, PGA2, PGB1, PGB2, PGD1, PGD2, PDJ2, 15-deoxy-12,14-delta-PGJ2, and 12-delta-PGJ2.

### Claim 18 (depends on 12)

The method of claim 12, wherein the PPAR gamma ligand is a fatty acid containing about 10 to about 26 carbon atoms and zero to about 6 carbon-carbon double bonds or carbon-carbon triple bonds.

### Claim 19

A method of providing an article of manufacture for inhibiting angiogenesis in a patient, comprising the step of providing:
(a) a container comprising a composition having a therapeutically effective amount of a PPAR gamma ligand therein; and
(b) an indication that the composition can be used to inhibit angiogenesis.

### Claim 20 (depends on 19)

The method of claim 19, wherein the patient is a mammal.

### Claim 21 (depends on 20)

The method of claim 20, wherein the mammal is human.

### Claim 22 (depends on 19)

The method of claim 19, wherein the therapeutically effective amount of a PPAR gamma ligand is an angiogenesis inhibiting amount.

### Claim 23 (depends on 19)

The method of claim 19, further comprising the step of providing a composition comprising a therapeutically effective amount of an RXR receptor ligand.

### Claim 24 (depends on 19)

The method of claim 19, wherein the PPAR gamma ligand is selected from the group consisting of (+)-5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione: (troglitazone); 5-[4-[2-(5-ethylpyridin-2-yl)ethoxyl]benzyl]thiadiazolidine-2,4-dione: (pioglitazone); 5-[4-[(1-methylcyclohexyl)methoxy]benzyl]thiadiazolidine-2,4-dione: (ciglitazone); 4-(2-naphthylmethyl)-1,2,3,5-oxathiadiazole-2-oxide; 5-[4-[2-[N-(benzoxazol-2-yl)-N-methylamino]ethoxy]benzyl]-5-methylthiazolidine-2,4-dione; 5-[4-[-[2,4-dioxo-5-phenylthiazolidin-3-yl) ethoxy]benzyl]thiazolidine-2,4-dione; 5-[4-[2[N-methyl-N-(phenoxycarbonyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione; 5-[4-[2-phenoxyethoxy)benzyl]thiazolidine-2,4-dione; 5-[4-[2-(4-chlorophenyl) ethylsulfonyl]benzyl]thiazolidine-2,4-dione; 5-[4-[3-(5-methyl-2-phenyloxazol-4-yl)propionyl]benzyl]thiazolidine-2,4-dione; 5-[[4-(3-hydroxy-1-methylcyclohexyl)methoxy]benzyl]thiadiazolidine-2,4-dione; 5-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxyl]benzyl]thiadiazolidione-2,4-dione; 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-ylmethyl]thiadiazoline-2,4-dione: (englitazone); 5-[[2-(2-naphthylmethyl)benzoxazol]-5-ylmethyl]thiadiazoline-2,4-dione; 5-[4-[2-(3-phenylureido)ethoxyl]benzyl]thiadiazoline-2,4-dione; 5-[4-[2-[N-(benzoxazol-2-yl)-N-methylamino]ethoxy]benzy]thiadiazoline-2,4-dione; 5-[4-[3-(5-methyl-2-phenyloxazol-4-yl)propionyl]benzyl]thiadiazoline-2,4-dione; 5-[2-(5-methyl-2-phenyloxazol-4-ylmethyl)benzofuran-5-ylmethyl]-oxazolidine-, 4-dione; 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione (BRL 49653); and 5-[4-[2-[N-(benzoxazol-2-yl)-N-methylamino]ethoxy]benzyl]-oxazolidine-2,4-dione.

### Claim 25 (depends on 19)

The method of claim 19, wherein the PPAR gamma ligand is selected from the group consisting of PGA1, PGA2, PGB1, PGB2, PGD1, PGD2, PDJ2, 15-deoxy-12,14-delta-PGJ2, and 12-delta-PGJ2.

### Claim 26 (depends on 19)

The method of claim 19, wherein the PPAR gamma ligand is a fatty acid containing about 10 to about 26 carbon atoms and zero to about 6 carbon-carbon double bonds or carbon-carbon triple bonds.

### Claim 27 (depends on 19)

The method of claim 19, wherein a label provides the indication.

### Claim 28 (depends on 19)

An article of manufacture for inhibiting angiogenesis prepared by the method of claim 19.

### Claim 29

An article of manufacture for inhibiting angiogenesis comprising:
(a) a container;
(b) a composition within the container comprising a therapeutically effective amount of a PPAR gamma ligand; and
(c) an indication that the composition can be used to inhibit angiogenesis.
